Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response

Endocrine-Related Cancer

Volumn 20, Issue 5, 2013, Pages 691-704

  Lazaro, Glorianne ^a   Smith, Chris ^a   Goddard, Lindy ^a   Jordan, Nicola ^a   McClelland, Richard ^a   Barrett Lee, Peter ^a,b   Nicholson, Robert I ^a   Hiscox, Stephen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Breast cancer; Focal adhesion kinase; Growth factor receptor 2; HER2; Human epidermal; Luminal B breast cancer; Trastuzumab

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FOCAL ADHESION KINASE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEU DIFFERENTIATION FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL ACTIVATION; CELL ACTIVITY; CELL DIVISION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; HUMAN; MONOTHERAPY; SIGNAL TRANSDUCTION; TARGET CELL; TREATMENT RESPONSE;

EID: 84886414343     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0019     Document Type: Article

References (56)

1. Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LX, Meslin F, Spielmann M, Tomasic G, Pusztai L et al. 2008 Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Annals of Oncology 19 315-320. (doi:10.1093/annonc/mdm429)
2. Arribas J, Baselga J, Pedersen K & Parra-Palau JL 2011 p95HER2 and breast cancer. Cancer Research 71 1515-1519. (doi:10.1158/0008-5472. CAN-10-3795)
3. Bauer K, Parise C & Caggiano V 2010 Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen consensus statement for early breast cancer. BMC Cancer 10 228. (doi:10.1186/1471-2407-10-228)
4. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M et al. 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 395-402. (doi:10.1016/j.ccr.2007.08.030)
5. Bhargava R, Dabbs DJ, Beriwal S, Yildiz IA, Badve P, Soran A, Johnson RR, Brufsky AM, Lembersky BC, McGuire KP et al. 2011 Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Modern Pathology 24 367-374. (doi:10.1038/modpathol.2010.209)
6. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A et al. 2012 Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse. Annals of Oncology 24 661-668. (doi:10.1093/ annonc/mds430)
7. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, CarverME & Shepard HM1992 Humanization of an anti-p185HER2 antibody for human cancer therapy. PNAS 89 4285-4289. (doi:10.1073/pnas.89.10. 4285)
8. Chen YY, Wang ZX, Chang PA, Li JJ, Pan F, Yang L, Bian ZH, Zou L, He JM & Liang HJ 2009 Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance. Cancer Science 100 1708-1713. (doi:10.1111/j.1349- 7006.2009.01217.x)
9. Cicchini C, Laudadio I, Citarella F, Corazzari M, Steindler C, Conigliaro A, Fantoni A, Amicone L & Tripodi M 2008 TGFb-induced EMT requires focal adhesion kinase (FAK) signaling. Experimental Cell Research 314 143-152. (doi:10.1016/j.yexcr.2007.09.005)
10. Eke I & Cordes N 2011 Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. Radiotherapy and Oncology 99 279-286. (doi:10.1016/j.radonc.2011.06.006)
11. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, Gonzalez-Angulo AM, Mills GB, Penuel E, Winslow J et al. 2011 Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Research 71 1871-1882. (doi:10.1158/0008- 5472.CAN-10-1872)
12. Gijsen M, King P, Perera T, Parker P, Larijani B, Harris A & Kong A 2010a Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer. Breast Cancer Research 12 (Suppl 1) O2. (doi:10.1186/ bcr2493)
13. Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B & Kong A 2010b HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biology 8 e1000563. (doi:10.1371/journal.pbio.1000563)
14. Golubovskaya V, Beviglia L, Xu LH, Earp HS III, Craven R & CanceW2002 Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. Journal of Biological Chemistry 277 38978-38987. (doi:10.1074/jbc.M205002200)
15. Guiu S, Michiels S, Andre F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N et al. 2012 Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement Annals of Oncology 23 2997-3006. (doi:10.1093/annonc/mds586)
16. Halder J, Lin YG, MerrittWM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C et al. 2007 Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Research 67 10976-10983. (doi:10.1158/0008-5472.CAN-07-2667)
17. Han EK, McGonigal T, Wang J, Giranda VL & Luo Y 2004 Functional analysis of focal adhesion kinase (FAK) reduction by small inhibitory RNAs. Anticancer Research 24 3899-3905.
18. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM & Press MF 2012 Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiology, Biomarkers & Prevention 21 1848-1855. (doi:10.1158/ 1055-9965.EPI-12-0474)
19. Hehlgans S, Eke I&CordesN2012 Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling. International Journal of Radiation Oncology, Biology, Physics 83 e669-e676. (doi:10.1016/j.ijrobp.2012.01.065)
20. Hiscox S, Barnfather P, Hayes E, Bramble P, Christensen J, Nicholson RI & Barrett-Lee P 2011 Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Research and Treatment 125 659-669. (doi:10.1007/s10549-010-0857-4)
21. Hynes NE, Gerber HA, Saurer S & Groner B 1989 Overexpression of the c-erbB-2 protein in human breast tumor cell lines. Journal of Cellular Biochemistry 39 167-173. (doi:10.1002/jcb.240390208)
22. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG et al. 2012 Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. Journal of Clinical Oncology 30 1527-1533. (doi:10.1200/ JCO.2011.38.9346)
23. Ishitobi M,OkumuraY,ArimaN, Yoshida A, Nakatsukasa K, IwaseT, Shien T, Masuda N, Tanaka S, Tanabe M et al. 2013 Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence. Annals of Surgical Oncology 20 1886-1892. (doi:10.1245/s10434-012-2825-1)
24. Itoh S, Maeda T, Shimada M, Aishima S, Shirabe K, Tanaka S & Maehara Y 2004 Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clinical Cancer Research 10 2812-2817. (doi:10.1158/1078-0432.CCR-1046-03)
25. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D & Sliwkowski MX 2009 Ligand-independent HER2/HER3/ PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15 429-440. (doi:10.1016/ j.ccr.2009.03.020)
26. Kurenova E, Xu LH, Yang X, Baldwin AS Jr, Craven RJ, Hanks SK, Liu ZG & CanceWG2004 Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Molecular and Cellular Biology 24 4361-4371. (doi:10.1128/MCB.24.10.4361-4371.2004)
27. Lark AL, Livasy CA,Dressler L, Moore DT, Millikan RC, Geradts J, Iacocca M, Cowan D, Little D, Craven RJ et al. 2005 High focal adhesion kinase expression in invasive breast carcinomas is associatedwith an aggressive phenotype. Modern Pathology 18 1289-1294. (doi:10.1038/modpathol. 3800424)
28. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX & Stern HM 2008 A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Research 68 5878-5887. (doi:10.1158/0008-5472.CAN-08-0380)
29. Lin HJ, Hsieh FC, Song H & Lin J 2005 Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. British Journal of Cancer 93 1372-1381. (doi:10.1038/sj.bjc.6602862)
30. Menendez JA, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A, Garcia-Villalba R, Fernandez-GutierrezA&Segura-CarreteroA2007Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptine) in HER2-overexpressing breast cancer cells. BMC Cancer 7 80. (doi:10.1186/1471- 2407-7-80)
31. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A et al. 2009 Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. Journal of Clinical Oncology 27 4701-4708. (doi:10.1200/JCO. 2008.21.7075)
32. Mitra SK, Hanson DA & Schlaepfer DD 2005 Focal adhesion kinase: in command and control of cell motility. Nature Reviews. Molecular Cell Biology 6 56-68. (doi:10.1038/nrm1549)
33. Nahta R 2012 Pharmacological strategies to overcome HER2 cross-talk and trastuzumab resistance. Current Medicinal Chemistry 19 1065-1075. (doi:10.2174/092986712799320691)
34. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL & Harris JR 2008 Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. Journal of Clinical Oncology 26 2373-2378. (doi:10.1200/JCO. 2007.14.4287)
35. Parise CA, Bauer KR, Brown MM& Caggiano V 2009 Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR) , and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast Journal 15 593-602. (doi:10.1111/j.1524-4741.2009.00822.x)
36. Park S, Koo JS, Kim MS, Park HS, Lee JS, Kim SI & Park BW 2012 Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21 50-57. (doi:10.1016/j.breast.2011.07.008)
37. Ponnusamy MP, Singh AP, Jain M, Chakraborty S, Moniaux N & Batra SK 2008 MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. British Journal of Cancer 99 520-526. (doi:10.1038/sj.bjc.6604517)
38. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal ofMedicine353 1673-1684. (doi:10.1056/NEJMoa052122)
39. Schmitz KJ, Grabellus F, Callies R, Otterbach F,Wohlschlaeger J, Levkau B, Kimmig R, SchmidKW&BabaHA2005Highexpression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Research 7 R194-R203. (doi:10.1186/bcr977)
40. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH & Schlaepfer DD 2000 FAK integrates growth-factor and integrin signals to promote cell migration. Nature Cell Biology 2 249-256. (doi:10.1038/ 35010517)
41. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG et al. 2007 Cellular characterization of a novel focal adhesion kinase inhibitor. Journal of Biological Chemistry 282 14845-14852. (doi:10.1074/jbc.M606695200)
42. Smith CS, Golubovskaya VM, Peck E, Xu LH, Monia BP, Yang X & Cance WG 2005 Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Research 15 357-362. (doi:10.1097/ 00008390-200510000-00003)
43. Steel GG & Peckham MJ 1979 Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. International Journal of Radiation Oncology, Biology, Physics 5 85-91. (doi:10.1016/ 0360-3016(79) 90044-0)
44. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Lim ST, Liang C, Koenig M, Sun C et al. 2010 PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biology & Therapy 9 764-777. (doi:10.4161/cbt.9.10.11434)
45. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B et al. 2008 Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Annals of Oncology 19 1090-1096. (doi:10.1093/annonc/mdn005)
46. Vadlamudi RK, Adam L, Nguyen D, Santos M & Kumar R 2002 Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2. Journal of Cellular Physiology 190 189-199. (doi:10.1002/jcp.10054)
47. Vadlamudi RK, Sahin AA, Adam L, Wang RA & Kumar R 2003 Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Letters 543 76-80. (doi:10.1016/S0014- 5793(03) 00404-6)
48. Vogel CL, CobleighMA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M et al. 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20 719-726. (doi:10.1200/JCO.20.3.719)
49. Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, Phillips A, Patel N, Kwok C, McMahon G et al. 2010 Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biology & Therapy 9 778-790. (doi:10.4161/cbt.9.10.11433)
50. Wang SE, Wu FY, Shin I, Qu S & Arteaga CL 2005 Transforming growth factor {b} (TGF-{b})-Smad target gene protein tyrosine phosphatase receptor type k is required for TGF-{b} function. Molecular and Cellular Biology 25 4703-4715. (doi:10.1128/MCB.25.11.4703-4715.2005)
51. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A & Arteaga CL 2009 Transforming growth factor b induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Research 69 475-482. (doi:10.1158/0008-5472. CAN-08-2649)
52. Worzfeld T, Swiercz JM, LoosoM, Straub BK, Sivaraj KK & Offermanns S 2012 ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis. Journal of Clinical Investigation 122 1296-1305. (doi:10.1172/JCI60568)
53. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE & Hemler ME 2010 Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Research 70 2256-2263. (doi:10.1158/0008-5472.CAN-09-4032)
54. Yao E, ZhouW,Lee-Hoeflich ST, Truong T,Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ et al. 2009 Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clinical Cancer Research 15 4147-4156. (doi:10.1158/1078-0432.CCR-08-2814)
55. Zheng D, Golubovskaya V, Kurenova E, Wood C, Massoll NA, Ostrov D, Cance WG & Hochwald SN 2010 A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Molecular Carcinogenesis 49 200-209.
56. Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma Y & Zhang J 2012 Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumor Biology.